# A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

> **NCT01513083** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 28 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab emtansine

## Key facts

- **NCT ID:** NCT01513083
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513083, "A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01513083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*